This report provides a comprehensive analysis of the global wound dressings market, which is projected to experience significant growth through 2030. Driven by an increasing prevalence of chronic wounds, surgical interventions, and traumatic injuries, the market is seeing high demand for advanced wound dressings that offer superior healing outcomes. While high costs present a potential restraint, technological advancements and an aging population continue to fuel expansion. The Asia Pacific region is identified as the fastest-growing market due to rising healthcare investments and medical tourism.

Market Overview

The global wound dressings market is projected to grow from USD 11.60 billion in 2025 to USD 15.87 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5% during the forecast period.

Market Dynamics

Growth Drivers

• Rising incidence of burn injuries.
• Increasing prevalence of chronic, surgical, and traumatic wounds.
• High rate of cesarean sections among elderly women.
• Growing number of road accidents.

Market Restraints

• High cost of advanced wound dressings.
• Limited adoption of advanced wound dressings.

Market Segmentation

By Type

• Traditional Wound Dressings
• Advanced Wound Dressings: This segment accounted for the largest share of the market by type in 2024. Growth is driven by the increasing incidence of chronic wounds (such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers) requiring specialized treatment. Additional drivers include the rising prevalence of diabetes, increased patient awareness regarding wound management, advancements in wound care technologies, and the growing burden of hospital-acquired infections (HAIs). These products are preferred for offering faster healing, reduced infection risk, and improved patient outcomes.

By Wound Type

• Surgical and Traumatic Wounds: This segment held the largest market share in 2024. Dominance is attributed to the rising number of surgical interventions worldwide and the increasing incidence of traumatic injuries from accidents and falls. The growing elderly population and the global rise in road traffic accidents further support this segment. It is projected to witness the highest CAGR during the forecast period due to continuous improvements in surgical techniques, post-operative care, and increased use in both hospital and home care settings.
• Diabetic Foot Ulcers
• Pressure Ulcers
• Venous Leg Ulcers
• Burns & Other Wounds

By Region

The global market is categorized into five key regions:

• North America
• Europe
• Asia Pacific: Identified as the fastest-growing region. Growth is fueled by an aging population, rising prevalence of lifestyle-related conditions causing chronic wounds, increasing demand for high-quality healthcare, and substantial investments in hospital infrastructure and medical technologies. Furthermore, the growing medical tourism industry in countries like India, Thailand, and Singapore is driving surgical procedures and the subsequent need for post-operative wound care. Asia Pacific is expected to register the highest CAGR during the forecast period.
• Latin America
• Middle East & Africa

Competitive Landscape

Primary Participant Breakdown

By Company Type:

• Tier 1: 40%
• Tier 2: 30%
• Tier 3: 30%

(Note: Tier 1 >USD 10.00 billion; Tier 2 = USD 1.00 billion to USD 10.00 billion; Tier 3 <USD 1.00 billion as of 2023)

By Designation:

• C-Level: 27% (Includes CEOs, CFOs, COOs, and VPs)
• Director Level: 18%
• Others: 55% (Includes sales managers, marketing managers, business development managers, product managers, distributors, and suppliers)

By Region:

• North America: 51%
• Europe: 21%
• Asia Pacific: 18%
• Latin America: 6%
• Middle East & Africa: 4%

Major Players

• Advancis (UK)
• B.Braun SE (Germany)
• Cardinal Health (US)
• Coloplast Group (Denmark)
• Convatec Group PLC (UK)
• DeRoyal Industries, Ine. (US)
• DermaRite Industries, LLC. (US)
• Essity Aktiebolag (Sweden)
• Focus Health Group (US)
• Gentell (US)
• Hollister Incorporated (US)
• Integra LifeSciences Corporation (US)
• Lohmann & Rausher GmbH & Co. KG (Germany)
• Mativ Holdings, Inc. (US)
• Medline Industries, LP (US)
• Mil Laboratories Pvt. Ltd. (India)
• Mölnlycke AB (Sweden)
• Owens & Minor (US)
• PAUL HARTMANN AG (Germany)
• Shield Line (US)
• Smith+ Nephew (UK)
• Solventum (US)
• Urgo Group (France)
• Winner Medical Co., LTD. (China)

Research Coverage

This report provides a comprehensive study of the wound dressings market based on:

• Segmentation: Type, wound type, end user, and country.
• Market Factors: Drivers, restraints, opportunities, and challenges.
• Competitive Analysis: Details on market leaders and micro-market growth trends.
• Forecasting: Revenue forecasts for market segments across five major regions and their respective countries.

Strategic Value (Reasons to Buy)

This report serves as a tool for both established firms and new entrants to gauge market trends and increase market share through the following insights:

• Analysis of Key Drivers: Growing geriatric population, increasing traumatic injuries, prevalence of chronic diseases, rising burn injuries, use of regenerative medicine, and government/reimbursement policies.
• Analysis of Restraints: High cost of advanced products, risks associated with advanced care, and antimicrobial resistance challenges.
• Identification of Opportunities: Growth in emerging economies, technological advancements, and home-care optimized solutions.
• Identification of Challenges: Lack of trained healthcare professionals, limited awareness in underdeveloped regions, and data security/privacy concerns.
• Market Penetration: Information on product portfolios of top players.
• Product Development/Innovation: Insights into upcoming trends, R&D, and product launches.
• Market Development: Information on lucrative emerging regions.
• Market Diversification: Data on new products, growing geographies, and recent developments.
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and leading player products.

• 1 INTRODUCTION 30

  • 1.1 STUDY OBJECTIVES 30

  • 1.2 MARKET DEFINITION 30

  • 1.3 STUDY SCOPE 31

    • 1.3.1 MARKETS COVERED & REGIONAL SCOPE 31

    • 1.3.2 INCLUSIONS & EXCLUSIONS 32

    • 1.3.3 YEARS CONSIDERED 33

  • 1.4 CURRENCY CONSIDERED 33

  • 1.5 STAKEHOLDERS 33

  • 1.6 SUMMARY OF CHANGES 34

• 2 RESEARCH METHODOLOGY 35

  • 2.1 RESEARCH DATA 35

    • 2.1.1 SECONDARY DATA 36

      • 2.1.1.1 Key data from secondary sources 36

    • 2.1.2 PRIMARY DATA 37

      • 2.1.2.1 Primary sources 37
      • 2.1.2.2 Key industry insights 38
      • 2.1.2.3 Key data from primary sources 38
      • 2.1.2.4 Breakdown of primary interviews 39

  • 2.2 MARKET SIZE ESTIMATION 40

    • 2.2.1 BOTTOM-UP APPROACH 40

      • 2.2.1.1 Approach 1: Company revenue estimation approach 40
      • 2.2.1.2 Approach 2: Presentations of companies and primary interviews 41
      • 2.2.1.3 Approach 3: Primary interviews 41
      • 2.2.1.4 Growth forecast 41
      • 2.2.1.5 CAGR projections 42

    • 2.2.2 TOP-DOWN APPROACH 42

  • 2.3 MARKET BREAKDOWN & DATA TRIANGULATION 43

  • 2.4 RESEARCH ASSUMPTIONS 44

    • 2.4.1 STUDY-RELATED ASSUMPTIONS 44

    • 2.4.2 PARAMETRIC ASSUMPTIONS 44

  • 2.5 RESEARCH LIMITATIONS 44

  • 2.6 RISK ASSESSMENT 45

• 3 EXECUTIVE SUMMARY 46

• 4 PREMIUM INSIGHTS 50

  • 4.1 WOUND DRESSINGS MARKET OVERVIEW 50

  • 4.2 ASIA PACIFIC: WOUND DRESSINGS MARKET SHARE, BY END USER AND COUNTRY 51

  • 4.3 WOUND DRESSINGS MARKET: GEOGRAPHIC SNAPSHOT 52

  • 4.4 WOUND DRESSINGS MARKET, REGIONAL MIX, 2025 VS. 2030 52

• 5 MARKET OVERVIEW 53

  • 5.1 INTRODUCTION 53

  • 5.2 MARKET DYNAMICS 53

    • 5.2.1 DRIVERS 54

      • 5.2.1.1 Increasing burden of chronic illnesses and conditions that impair natural wound healing 54
      • 5.2.1.2 Rising cases of burn-related injuries globally 55
      • 5.2.1.3 Increasing number of road accidents and trauma injuries 56
      • 5.2.1.4 Elevated rate of cesarean deliveries in elderly mothers 57
      • 5.2.1.5 Technological advancements in wound dressings 58

    • 5.2.2 RESTRAINTS 59

      • 5.2.2.1 High cost of advanced wound dressings 59
      • 5.2.2.2 Potential risks and complications linked to wound dressings 60
      • 5.2.2.3 Antimicrobial resistance challenges 60

    • 5.2.3 OPPORTUNITIES 61

      • 5.2.3.1 Growth opportunities in emerging economies 61
      • 5.2.3.2 Supportive government initiatives and favorable reimbursement frameworks 61

    • 5.2.4 CHALLENGES 62

      • 5.2.4.1 Lack of trained healthcare professionals 62
      • 5.2.4.2 Gaps in awareness and accessibility across emerging markets 62

  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 63

  • 5.4 PRICING ANALYSIS 63

    • 5.4.1 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2023-2025 64

    • 5.4.2 AVERAGE SELLING PRICE TREND OF WOUND DRESSING PRODUCTS FOR KEY WOUND TYPES, BY KEY PLAYER, 2023-2025 64

    • 5.4.3 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 65

  • 5.5 VALUE CHAIN ANALYSIS 65

  • 5.6 SUPPLY CHAIN ANALYSIS 67

  • 5.7 ECOSYSTEM ANALYSIS 68

  • 5.8 INVESTMENT & FUNDING SCENARIO 69

  • 5.9 TECHNOLOGY ANALYSIS 70

    • 5.9.1 KEY TECHNOLOGIES 70

      • 5.9.1.1 Bioactive wound dressings 70

    • 5.9.2 COMPLEMENTARY TECHNOLOGIES 71

      • 5.9.2.1 Antimicrobial coating technology 71

    • 5.9.3 ADJACENT TECHNOLOGIES 71

      • 5.9.3.1 Negative-pressure wound therapy 71

  • 5.10 PATENT ANALYSIS 72

  • 5.11 TRADE ANALYSIS 74

    • 5.11.1 IMPORT SCENARIO 74

    • 5.11.2 EXPORT SCENARIO 75

  • 5.12 KEY CONFERENCES & EVENTS, 2025-2026 76

  • 5.13 CASE STUDY ANALYSIS 77

    • 5.13.1 CASE STUDY 1: HYDROCOLL HYDROCOLLOID DRESSINGS ACCELERATE HEALING IN CHRONIC WOUNDS 77

    • 5.13.2 CASE STUDY 2: BIATAIN SILICONE ENHANCES COMFORT AND HEALING IN CHRONIC WOUNDS 78

    • 5.13.3 CASE STUDY 3: MEPILEX UP REDUCES LEAKAGE AND IMPROVES LIFE QUALITY IN VENOUS LEG ULCERS 78

  • 5.14 REGULATORY ANALYSIS 79

    • 5.14.1 REGULATORY LANDSCAPE 79

      • 5.14.1.1 North America 79
        • 5.14.1.1.1 US 79
        • 5.14.1.1.2 Canada 79
      • 5.14.1.2 Europe 79
        • 5.14.1.2.1 Germany 80
        • 5.14.1.2.2 UK 80
        • 5.14.1.2.3 France 80
      • 5.14.1.3 Asia Pacific 80
        • 5.14.1.3.1 China 80
        • 5.14.1.3.2 Japan 81
        • 5.14.1.3.3 India 81
      • 5.14.1.4 Latin America 81
      • 5.14.1.5 Middle East 82

    • 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82

      • 5.14.2.1 North America 82
      • 5.14.2.2 Europe 82
      • 5.14.2.3 Asia Pacific 83
      • 5.14.2.4 Latin America 83
      • 5.14.2.5 Rest of the World 84

  • 5.15 PORTER’S FIVE FORCES ANALYSIS 84

    • 5.15.1 BARGAINING POWER OF SUPPLIERS 85

    • 5.15.2 BARGAINING POWER OF BUYERS 85

    • 5.15.3 THREAT OF NEW ENTRANTS 85

    • 5.15.4 THREAT OF SUBSTITUTES 85

    • 5.15.5 INTENSITY OF COMPETITIVE RIVALRY 86

  • 5.16 KEY STAKEHOLDERS & BUYING CRITERIA 86

    • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 86

    • 5.16.2 BUYING CRITERIA 87

  • 5.17 IMPACT OF AI ON WOUND DRESSINGS MARKET 88

    • 5.17.1 INTRODUCTION 88

    • 5.17.2 MARKET POTENTIAL OF AI IN WOUND DRESSINGS MARKET 88

    • 5.17.3 IMPACT OF AI ON WOUND DRESSINGS MARKET: USE CASES 89

    • 5.17.4 KEY COMPANIES IMPLEMENTING AI 90

    • 5.17.5 FUTURE OF AI IN WOUND DRESSINGS MARKET 90

  • 5.18 IMPACT OF US 2025 TARIFFS ON WOUND DRESSINGS MARKET 90

    • 5.18.1 INTRODUCTION 90

    • 5.18.2 KEY TARIFF RATES 91

    • 5.18.3 PRICE IMPACT ANALYSIS 92

    • 5.18.4 IMPACT ON COUNTRY/REGION 92

      • 5.18.4.1 North America 92
      • 5.18.4.2 Europe 92
      • 5.18.4.3 Asia Pacific 92

    • 5.18.5 IMPACT ON END-USE INDUSTRIES 93

      • 5.18.5.1 Hospitals, ASCs, and clinics 93

• 6 WOUND DRESSINGS MARKET, BY TYPE 94

  • 6.1 INTRODUCTION 95

  • 6.2 ADVANCED WOUND DRESSINGS 95

    • 6.2.1 FOAM DRESSINGS 98

      • 6.2.1.1 Silicone dressings 102
        • 6.2.1.1.1 Ability of silicone dressings to expedite wound closure and reduce risk of maceration to drive market 102
      • 6.2.1.2 Non-silicone dressings 104
        • 6.2.1.2.1 Advantages such as scar removal and wound healing to drive demand for non-silicone dressings 104

    • 6.2.2 HYDROCOLLOID DRESSINGS 106

      • 6.2.2.1 Ability to promote granulation and formation of new tissues in open wounds to boost adoption 106

    • 6.2.3 FILM DRESSINGS 109

      • 6.2.3.1 Non-absorbable nature of film dressings to limit adoption 109

    • 6.2.4 ALGINATE DRESSINGS 112

      • 6.2.4.1 Growing incidence of pressure and diabetic foot ulcers to fuel growth 112

    • 6.2.5 HYDROGEL DRESSINGS 114

      • 6.2.5.1 Ability to provide relief and cooling effect on skin to drive use of hydrogel dressings 114

    • 6.2.6 COLLAGEN DRESSINGS 117

      • 6.2.6.1 Favorable reimbursement scenario for collagen dressings to support market 117

    • 6.2.7 HYDROFIBER DRESSINGS 120

      • 6.2.7.1 Combination of properties of hydrocolloids and alginates to boost adoption of hydrofiber dressings 120

    • 6.2.8 WOUND CONTACT LAYERS 122

      • 6.2.8.1 Ability to protect wound beds from bacterial and fungal growth to drive growth 122

    • 6.2.9 SUPERABSORBENT DRESSINGS 125

      • 6.2.9.1 Use of superabsorbent dressings for fragile skin to promote growth 125

    • 6.2.10 OTHER ADVANCED WOUND DRESSINGS 128

  • 6.3 TRADITIONAL WOUND DRESSINGS 131

    • 6.3.1 GAUZES 134

      • 6.3.1.1 Wide usage of gauzes in surgeries and wound packing to propel market growth 134

    • 6.3.2 TAPES 137

      • 6.3.2.1 Importance of secure fixation, comfort, and reduced trauma to drive demand 137

    • 6.3.3 BANDAGES 140

      • 6.3.3.1 Wide usage of bandages to support market growth 140

    • 6.3.4 ABSORBENT PADS 142

      • 6.3.4.1 Wide usage of absorbent pads in wound dressing and exudate management to drive market 142

    • 6.3.5 OTHER TRADITIONAL WOUND DRESSINGS 145

• 7 WOUND DRESSINGS MARKET, BY WOUND TYPE 148

  • 7.1 INTRODUCTION 149

  • 7.2 SURGICAL & TRAUMATIC WOUNDS 149

    • 7.2.1 GROWING VOLUME OF SURGICAL PROCEDURES PERFORMED AND INCREASING INCIDENCE OF BURN INJURIES TO SUPPORT MARKET GROWTH 149

  • 7.3 DIABETIC FOOT ULCERS 153

    • 7.3.1 INCREASING PREVALENCE OF DIABETES TO PROPEL MARKET GROWTH 153

  • 7.4 PRESSURE ULCERS 157

    • 7.4.1 GROWING PREVALENCE OF PRESSURE ULCERS TO SUPPORT MARKET GROWTH 157

  • 7.5 VENOUS LEG ULCERS 160

    • 7.5.1 RISING GERIATRIC POPULATION TO SUPPORT GROWTH OF THIS SEGMENT 160

  • 7.6 BURNS & OTHER WOUNDS 163

    • 7.6.1 HIGH INCIDENCE OF BURN INJURIES IN EMERGING COUNTRIES TO PROPEL GROWTH 163

• 8 WOUND DRESSINGS MARKET, BY END USER 167

  • 8.1 INTRODUCTION 168

  • 8.2 HOSPITALS, ASCS, AND CLINICS 168

    • 8.2.1 RISING NEED FOR BETTER WOUND MANAGEMENT AND GROWING NUMBER OF HOSPITAL READMISSIONS TO SUPPORT MARKET GROWTH 168

  • 8.3 HOME CARE SETTINGS 171

    • 8.3.1 NEED TO CONTROL RISING HEALTHCARE COSTS TO DRIVE MARKET GROWTH 171

  • 8.4 OTHER END USERS 174

• 9 WOUND DRESSINGS MARKET, BY REGION 178

  • 9.1 INTRODUCTION 179

  • 9.2 NORTH AMERICA 179

    • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 180

    • 9.2.2 US 183

      • 9.2.2.1 Rising diabetes prevalence and supportive reimbursement policies to drive market growth 183

    • 9.2.3 CANADA 186

      • 9.2.3.1 Government-backed efforts to support market development 186

  • 9.3 EUROPE 189

    • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 189

    • 9.3.2 GERMANY 195

      • 9.3.2.1 Rising diabetes cases and chronic wound burden to boost market growth 195

    • 9.3.3 FRANCE 198

      • 9.3.3.1 Rising chronic wound cases to drive market expansion in France 198

    • 9.3.4 UK 201

      • 9.3.4.1 Increase in R&D activity to propel market growth 201

    • 9.3.5 ITALY 204

      • 9.3.5.1 Growing number of injury-related cases in Italy to propel growth 204

    • 9.3.6 SPAIN 207

      • 9.3.6.1 Rising life expectancy and aging population to boost wound care adoption in Spain 207

    • 9.3.7 RUSSIA 210

      • 9.3.7.1 Government initiatives to raise diabetes awareness to support market expansion in Russia 210

    • 9.3.8 REST OF EUROPE 213

  • 9.4 ASIA PACIFIC 216

    • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 217

    • 9.4.2 CHINA 222

      • 9.4.2.1 Increasing incidence of diabetic foot ulcers (DFUs) to encourage growth 222

    • 9.4.3 JAPAN 225

      • 9.4.3.1 Evolving healthcare delivery and infrastructure landscape to fuel market 225

    • 9.4.4 INDIA 228

      • 9.4.4.1 Booming medical tourism to speed up market growth 228

    • 9.4.5 AUSTRALIA 231

      • 9.4.5.1 Growing number of medical manufacturing companies to drive market 231

    • 9.4.6 REST OF ASIA PACIFIC 234

  • 9.5 LATIN AMERICA 237

    • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 238

    • 9.5.2 BRAZIL 241

      • 9.5.2.1 Evolving healthcare infrastructure in country to contribute to growth 241

    • 9.5.3 MEXICO 244

      • 9.5.3.1 Expanding hospital infrastructure to aid growth 244

    • 9.5.4 REST OF LATIN AMERICA 247

  • 9.6 MIDDLE EAST & AFRICA 250

    • 9.6.1 GROWING DEMAND FOR HEALTHCARE FACILITIES TO DRIVE MARKET 250

• 10 COMPETITIVE LANDSCAPE 255

  • 10.1 OVERVIEW 255

  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2024 255

    • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN WOUND DRESSINGS MARKET 256

  • 10.3 REVENUE ANALYSIS, 2022-2024 257

  • 10.4 MARKET SHARE ANALYSIS, 2024 258

  • 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 260

    • 10.5.1 STARS 260

    • 10.5.2 EMERGING LEADERS 260

    • 10.5.3 PERVASIVE PLAYERS 261

    • 10.5.4 PARTICIPANTS 261

    • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 262

      • 10.5.5.1 Company footprint 262
      • 10.5.5.2 Region footprint 263
      • 10.5.5.3 Type footprint 264
      • 10.5.5.4 Wound type footprint 265
      • 10.5.5.5 End-user footprint 266

  • 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 267

    • 10.6.1 PROGRESSIVE COMPANIES 267

    • 10.6.2 RESPONSIVE COMPANIES 267

    • 10.6.3 DYNAMIC COMPANIES 267

    • 10.6.4 STARTING BLOCKS 267

    • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 269

      • 10.6.5.1 Detailed list of key startups/SMEs 269
      • 10.6.5.2 Competitive benchmarking of key startups/SMEs 270

  • 10.7 COMPANY VALUATION & FINANCIAL METRICS 271

    • 10.7.1 COMPANY VALUATION 271

    • 10.7.2 FINANCIAL METRICS 271

  • 10.8 BRAND/PRODUCT COMPARISON 272

  • 10.9 COMPETITIVE SCENARIO 272

    • 10.9.1 PRODUCT LAUNCHES & APPROVALS 272

    • 10.9.2 DEALS 273

    • 10.9.3 EXPANSIONS 274

    • 10.9.4 OTHER DEVELOPMENTS 275

• 11 COMPANY PROFILES 276

  • 11.1 KEY PLAYERS 276

    • 11.1.1 SOLVENTUM 276

      • 11.1.1.1 Business overview 276
      • 11.1.1.2 Products offered 277
      • 11.1.1.3 Recent developments 280
        • 11.1.1.3.1 Product launches & approvals 280
        • 11.1.1.3.2 Other developments 280
      • 11.1.1.4 MnM view 280
        • 11.1.1.4.1 Right to win 280
        • 11.1.1.4.2 Strategic choices 281
        • 11.1.1.4.3 Weaknesses & competitive threats 281

    • 11.1.2 MÖLNLYCKE AB 282

      • 11.1.2.1 Business overview 282
      • 11.1.2.2 Products offered 283
      • 11.1.2.3 Recent developments 285
        • 11.1.2.3.1 Deals 285
        • 11.1.2.3.2 Other developments 286
      • 11.1.2.4 MnM view 286
        • 11.1.2.4.1 Right to win 286
        • 11.1.2.4.2 Strategic choices 286
        • 11.1.2.4.3 Weaknesses & competitive threats 286

    • 11.1.3 CARDINAL HEALTH 287

      • 11.1.3.1 Business overview 287
      • 11.1.3.2 Products offered 288
      • 11.1.3.3 Recent developments 291
        • 11.1.3.3.1 Deals 291
        • 11.1.3.3.2 Expansions 292
      • 11.1.3.4 MnM view 293
        • 11.1.3.4.1 Right to win 293
        • 11.1.3.4.2 Strategic choices 293
        • 11.1.3.4.3 Weaknesses & competitive threats 293

    • 11.1.4 SMITH+NEPHEW 294

      • 11.1.4.1 Business overview 294
      • 11.1.4.2 Products offered 295
      • 11.1.4.3 Recent developments 297
        • 11.1.4.3.1 Deals 297
        • 11.1.4.3.2 Expansions 297
        • 11.1.4.3.3 Other developments 298
      • 11.1.4.4 MnM view 298
        • 11.1.4.4.1 Right to win 298
        • 11.1.4.4.2 Strategic choices 298
        • 11.1.4.4.3 Weaknesses & competitive threats 298

    • 11.1.5 CONVATEC GROUP PLC 299

      • 11.1.5.1 Business overview 299
      • 11.1.5.2 Products offered 300
      • 11.1.5.3 Recent developments 301
        • 11.1.5.3.1 Product launches 301
        • 11.1.5.3.2 Deals 301
      • 11.1.5.4 MnM view 302
        • 11.1.5.4.1 Right to win 302
        • 11.1.5.4.2 Strategic choices 302
        • 11.1.5.4.3 Weaknesses & competitive threats 302

    • 11.1.6 PAUL HARTMANN AG 303

      • 11.1.6.1 Business overview 303
      • 11.1.6.2 Products offered 304
      • 11.1.6.3 Recent developments 307
        • 11.1.6.3.1 Other developments 307

    • 11.1.7 COLOPLAST GROUP 308

      • 11.1.7.1 Business overview 308
      • 11.1.7.2 Products offered 309
      • 11.1.7.3 Recent developments 310
        • 11.1.7.3.1 Product launches 310

    • 11.1.8 OWENS & MINOR 311

      • 11.1.8.1 Business overview 311
      • 11.1.8.2 Products offered 312
      • 11.1.8.3 Recent developments 314
        • 11.1.8.3.1 Deals 314
        • 11.1.8.3.2 Other developments 315

    • 11.1.9 INTEGRA LIFESCIENCES CORPORATION 316

      • 11.1.9.1 Business overview 316
      • 11.1.9.2 Products offered 317
      • 11.1.9.3 Recent developments 318
        • 11.1.9.3.1 Other developments 318

    • 11.1.10 ESSITY AKTIEBOLAG 319

      • 11.1.10.1 Business overview 319
      • 11.1.10.2 Products offered 320
      • 11.1.10.3 Recent developments 323
        • 11.1.10.3.1 Other developments 323

    • 11.1.11 B. BRAUN SE 324

      • 11.1.11.1 Business overview 324
      • 11.1.11.2 Products offered 325

    • 11.1.12 ADVANCED MEDICAL SOLUTIONS GROUP PLC 327

      • 11.1.12.1 Business overview 327
      • 11.1.12.2 Products offered 328
      • 11.1.12.3 Recent developments 329
        • 11.1.12.3.1 Deals 329

    • 11.1.13 MATIV HOLDINGS, INC 330

      • 11.1.13.1 Business overview 330
      • 11.1.13.2 Products offered 331
      • 11.1.13.3 Recent developments 332
        • 11.1.13.3.1 Deals 332

  • 11.2 OTHER PLAYERS 333

    • 11.2.1 URGO GROUP 333

    • 11.2.2 DEROYAL INDUSTRIES, INC 334

    • 11.2.3 LOHMANN & RAUSCHER GMBH & CO. KG 335

    • 11.2.4 MEDLINE INDUSTRIES, LP 336

    • 11.2.5 WINNER MEDICAL CO., LTD 338

    • 11.2.6 ADVANCIS (UK) 339

    • 11.2.7 HOLLISTER INCORPORATED 340

    • 11.2.8 DERMARITE INDUSTRIES, LLC 341

    • 11.2.9 MIL LABORATORIES PVT. LTD 342

    • 11.2.10 GENTELL 343

    • 11.2.11 SHIELDLINE 344

    • 11.2.12 FOCUS HEALTH GROUP 345

• 12 APPENDIX 346

  • 12.1 DISCUSSION GUIDE 346

  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 349

  • 12.3 CUSTOMIZATION OPTIONS 351

  • 12.4 RELATED REPORTS 351

  • 12.5 AUTHOR DETAILS 352